PubMed:28738079 JSONTXT

{"project":"Zierdiyeerkenaili_800","denotations":[{"id":"T1","span":{"begin":73,"end":92},"obj":"DP"},{"id":"T2","span":{"begin":247,"end":266},"obj":"DP"},{"id":"T3","span":{"begin":454,"end":473},"obj":"DP"},{"id":"T4","span":{"begin":1868,"end":1887},"obj":"DP"},{"id":"T5","span":{"begin":35,"end":40},"obj":"CI"},{"id":"T6","span":{"begin":227,"end":232},"obj":"CI"},{"id":"T7","span":{"begin":549,"end":554},"obj":"CI"},{"id":"T8","span":{"begin":861,"end":866},"obj":"CI"},{"id":"T9","span":{"begin":1678,"end":1683},"obj":"CI"},{"id":"T10","span":{"begin":1777,"end":1782},"obj":"CI"},{"id":"T11","span":{"begin":556,"end":558},"obj":"CI"},{"id":"T12","span":{"begin":475,"end":477},"obj":"DP"},{"id":"T13","span":{"begin":621,"end":623},"obj":"DP"}],"text":"Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.\nOBJECTIVE: The aim of the trial was to determine the effectiveness of oxygen-ozone injections on knee osteoarthritis concerning pain reduction, joint functional improvement, and quality of life.\nMETHODS: In this randomized, double-blinded, placebo controlled clinical trial, 98 patients with symptomatic knee osteoarthritis (OA) were randomized into two groups receiving intra-articular 20 μg/ml of ozone (OZ) or placebo (PBO) for 8 weeks. The efficacy outcomes for knee OA were the Visual Analogue Scale (VAS), Lequesne Index, Timed Up and Go Test (TUG Test), SF-36, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Geriatric Pain Measure (GPM).\nRESULTS: After 8 weeks of treatment, ozone was more effective than the placebo: VAS [mean difference (MD) = 2.16, p \u003c 0.003 (CI 95% 0.42-3.89)], GPM [MD = 18.94, p \u003c 0.004 (CI 95% 3.43-34.44)], LEQ [MD = 4.05, p \u003c 0.001 (CI 95% 1.10-7.00)], WOMAC (P) [median of diff = 9.999, p = 0.019 (CI 95% 0.000-15.000)], WOMAC (JS) [median of diff = 12.499, p \u003c 0.001 (CI 95% 0.000-12.500)], WOMAC (PF) = [median of diff = 11.760, p = 0.003 (CI 95% 4.409-19.119)], TUG (no statistical difference) and SF-36 (FC) [(MD = -25.82, p \u003c 0.001 (CI 95% 33.65-17.99)], SF-36 (PH) [MD = -40.82, p \u003c 0.001 (CI 95% -54.48-27.17)], SF-36 (GSH) [MD = -3.38, p \u003c 0.001 (CI 95% -4.83-1.93)], SF-36 (SA) [MD = 2.17, p \u003c 0.001 (CI 95% -19.67-8.24), SF-36 (EA) [MD = -35.37, p \u003c 0.001 (CI 95% -48.86-21.89)]. Adverse events occurred in 3 patients (2 in the placebo group and 1 in the ozone group) and included only puncture accidents.\nCONCLUSIONS: The study confirms the efficacy of ozone concerning pain relief, functional improvement, and quality of life in patients with knee osteoarthritis.\nTRIAL REGISTRATION: International Standard Randomized Controlled Trial Number Register ISRCTNR55861167."}

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":549,"end":554},"obj":"CI"},{"id":"T10","span":{"begin":390,"end":397},"obj":"CI"},{"id":"T11","span":{"begin":895,"end":902},"obj":"CI"},{"id":"T12","span":{"begin":1651,"end":1658},"obj":"CI"},{"id":"T13","span":{"begin":563,"end":570},"obj":"CI"},{"id":"T14","span":{"begin":572,"end":575},"obj":"CI"},{"id":"T15","span":{"begin":454,"end":473},"obj":"DP"},{"id":"T16","span":{"begin":475,"end":477},"obj":"DP"},{"id":"T17","span":{"begin":73,"end":92},"obj":"DP"},{"id":"T18","span":{"begin":247,"end":266},"obj":"DP"},{"id":"T19","span":{"begin":1868,"end":1887},"obj":"DP"},{"id":"T2","span":{"begin":35,"end":40},"obj":"CI"},{"id":"T3","span":{"begin":861,"end":866},"obj":"CI"},{"id":"T4","span":{"begin":1678,"end":1683},"obj":"CI"},{"id":"T5","span":{"begin":1777,"end":1782},"obj":"CI"},{"id":"T7","span":{"begin":556,"end":558},"obj":"CI"},{"id":"T8","span":{"begin":45,"end":52},"obj":"CI"},{"id":"T9","span":{"begin":124,"end":131},"obj":"CI"},{"id":"T21","span":{"begin":227,"end":232},"obj":"CI"},{"id":"T22","span":{"begin":621,"end":623},"obj":"DP"}],"text":"Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.\nOBJECTIVE: The aim of the trial was to determine the effectiveness of oxygen-ozone injections on knee osteoarthritis concerning pain reduction, joint functional improvement, and quality of life.\nMETHODS: In this randomized, double-blinded, placebo controlled clinical trial, 98 patients with symptomatic knee osteoarthritis (OA) were randomized into two groups receiving intra-articular 20 μg/ml of ozone (OZ) or placebo (PBO) for 8 weeks. The efficacy outcomes for knee OA were the Visual Analogue Scale (VAS), Lequesne Index, Timed Up and Go Test (TUG Test), SF-36, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Geriatric Pain Measure (GPM).\nRESULTS: After 8 weeks of treatment, ozone was more effective than the placebo: VAS [mean difference (MD) = 2.16, p \u003c 0.003 (CI 95% 0.42-3.89)], GPM [MD = 18.94, p \u003c 0.004 (CI 95% 3.43-34.44)], LEQ [MD = 4.05, p \u003c 0.001 (CI 95% 1.10-7.00)], WOMAC (P) [median of diff = 9.999, p = 0.019 (CI 95% 0.000-15.000)], WOMAC (JS) [median of diff = 12.499, p \u003c 0.001 (CI 95% 0.000-12.500)], WOMAC (PF) = [median of diff = 11.760, p = 0.003 (CI 95% 4.409-19.119)], TUG (no statistical difference) and SF-36 (FC) [(MD = -25.82, p \u003c 0.001 (CI 95% 33.65-17.99)], SF-36 (PH) [MD = -40.82, p \u003c 0.001 (CI 95% -54.48-27.17)], SF-36 (GSH) [MD = -3.38, p \u003c 0.001 (CI 95% -4.83-1.93)], SF-36 (SA) [MD = 2.17, p \u003c 0.001 (CI 95% -19.67-8.24), SF-36 (EA) [MD = -35.37, p \u003c 0.001 (CI 95% -48.86-21.89)]. Adverse events occurred in 3 patients (2 in the placebo group and 1 in the ozone group) and included only puncture accidents.\nCONCLUSIONS: The study confirms the efficacy of ozone concerning pain relief, functional improvement, and quality of life in patients with knee osteoarthritis.\nTRIAL REGISTRATION: International Standard Randomized Controlled Trial Number Register ISRCTNR55861167."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T1","span":{"begin":35,"end":40},"obj":"CI"},{"id":"T10","span":{"begin":454,"end":473},"obj":"DP"},{"id":"T11","span":{"begin":1868,"end":1887},"obj":"DP"},{"id":"T12","span":{"begin":475,"end":477},"obj":"DP"},{"id":"T13","span":{"begin":621,"end":623},"obj":"DP"},{"id":"T14","span":{"begin":563,"end":570},"obj":"CI"},{"id":"T15","span":{"begin":45,"end":52},"obj":"CI"},{"id":"T16","span":{"begin":124,"end":131},"obj":"CI"},{"id":"T17","span":{"begin":390,"end":397},"obj":"CI"},{"id":"T18","span":{"begin":895,"end":902},"obj":"CI"},{"id":"T19","span":{"begin":1651,"end":1658},"obj":"CI"},{"id":"T2","span":{"begin":227,"end":232},"obj":"CI"},{"id":"T20","span":{"begin":572,"end":575},"obj":"CI"},{"id":"T3","span":{"begin":549,"end":554},"obj":"CI"},{"id":"T4","span":{"begin":861,"end":866},"obj":"CI"},{"id":"T5","span":{"begin":1678,"end":1683},"obj":"CI"},{"id":"T6","span":{"begin":1777,"end":1782},"obj":"CI"},{"id":"T7","span":{"begin":556,"end":558},"obj":"CI"},{"id":"T8","span":{"begin":73,"end":92},"obj":"DP"},{"id":"T9","span":{"begin":247,"end":266},"obj":"DP"}],"text":"Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.\nOBJECTIVE: The aim of the trial was to determine the effectiveness of oxygen-ozone injections on knee osteoarthritis concerning pain reduction, joint functional improvement, and quality of life.\nMETHODS: In this randomized, double-blinded, placebo controlled clinical trial, 98 patients with symptomatic knee osteoarthritis (OA) were randomized into two groups receiving intra-articular 20 μg/ml of ozone (OZ) or placebo (PBO) for 8 weeks. The efficacy outcomes for knee OA were the Visual Analogue Scale (VAS), Lequesne Index, Timed Up and Go Test (TUG Test), SF-36, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Geriatric Pain Measure (GPM).\nRESULTS: After 8 weeks of treatment, ozone was more effective than the placebo: VAS [mean difference (MD) = 2.16, p \u003c 0.003 (CI 95% 0.42-3.89)], GPM [MD = 18.94, p \u003c 0.004 (CI 95% 3.43-34.44)], LEQ [MD = 4.05, p \u003c 0.001 (CI 95% 1.10-7.00)], WOMAC (P) [median of diff = 9.999, p = 0.019 (CI 95% 0.000-15.000)], WOMAC (JS) [median of diff = 12.499, p \u003c 0.001 (CI 95% 0.000-12.500)], WOMAC (PF) = [median of diff = 11.760, p = 0.003 (CI 95% 4.409-19.119)], TUG (no statistical difference) and SF-36 (FC) [(MD = -25.82, p \u003c 0.001 (CI 95% 33.65-17.99)], SF-36 (PH) [MD = -40.82, p \u003c 0.001 (CI 95% -54.48-27.17)], SF-36 (GSH) [MD = -3.38, p \u003c 0.001 (CI 95% -4.83-1.93)], SF-36 (SA) [MD = 2.17, p \u003c 0.001 (CI 95% -19.67-8.24), SF-36 (EA) [MD = -35.37, p \u003c 0.001 (CI 95% -48.86-21.89)]. Adverse events occurred in 3 patients (2 in the placebo group and 1 in the ozone group) and included only puncture accidents.\nCONCLUSIONS: The study confirms the efficacy of ozone concerning pain relief, functional improvement, and quality of life in patients with knee osteoarthritis.\nTRIAL REGISTRATION: International Standard Randomized Controlled Trial Number Register ISRCTNR55861167."}